Close Menu

NEW YORK (GenomeWeb) – Thermo Fisher Scientific said today that its first quarter 2019 revenues grew five percent year over year, driven by strong results across all of its business segments.

The company, headquartered in Waltham, Massachusetts, reported Q1 revenues of $6.12 billion, up 5 percent from $5.85 billion during the same period last year, beating average expectations by Wall Street analysts of $6.02 billion. Organic revenue growth was 7 percent, acquisitions contributed 1 percent, and currency effects decreased revenue by 3 percent.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Researchers are developing a breath test to determine how severe patients' methylmalonic acidemia disease is, FierceBiotech reports.

NPR reports that vaccine developers are working on SARS-CoV-2 vaccines that are easier to store or administer than the current crop.

Reuters reports that France is to recommend that people under 55 who received one dose of AstraZeneca's SARS-CoV-2 vaccine receive a different vaccine for their second dose.